Biohaven Ltd is a biopharmaceutical company that focuses on developing innovative treatments for neurological and rare disorders
By harnessing advanced scientific research and drug development expertise, Biohaven aims to address unmet medical needs through their portfolio of promising therapies. The company's commitment to improving patient outcomes is reflected in their efforts to bring new, effective medications to market, particularly for conditions such as migraine and neurodegenerative diseases. Through rigorous clinical trials and a dedication to scientific excellence, Biohaven strives to enhance the quality of life for individuals affected by debilitating health issues.
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSEBHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics® technology platform, and Biohaven’s next-generation ADC conjugation and payload platform technologies.
Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) is the focus of IBN’s latest stock spotlight. The company’s shares have moved -0.78% on the day to $57.6.
Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 12.93% on the day to $55.95.
San Diego, CA -- (SBWIRE) -- 08/23/2023 -- Biohaven Ltd. is under investigation over potential securities laws violations in connection with certain financial statements.
Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 2.94% on the day to $27.63.
Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) traded at a new 52-week high today and are currently trading at $27.63. So far today, approximately 555.29k shares have been exchanged, as compared to an average 30-day volume of 1.31M shares.
Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) traded at a new 52-week high today and are currently trading at $26.77. So far today, approximately 89,503 shares have been exchanged, as compared to an average 30-day volume of 1.49M shares.
Pfizer Inc. (NYSEPFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) traded today at a new 52-week high of $152.56. This new high was reached on below average trading volume as 227,000 shares traded hands, while the average 30-day volume is approximately 738,000 shares.
Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) traded today at $152.16, eclipsing its 52-week high. Approximately 960,000 shares have changed hands today, as compared to an average 30-day volume of 680,000 shares.
Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) traded today at $152.13, eclipsing its 52-week high. Approximately 1.7 million shares have changed hands today, as compared to an average 30-day volume of 596,000 shares.
Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQVTRS), which produces products that treat diabetes, immunology and oncology.
Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven's troriluzole and Vigeo's VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) to Pfizer Inc. NYSE: PFENYSEPFE)
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSEBHVN) to Pfizer Inc. for $148.50 per share in cash is fair to Biohaven shareholders. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline compounds, per Biohaven common share.
2021 was a year to be easily forgotten for biotech stocks. The S&P 500 climbed 26.9%. However, SPDR S&P Biotech exchange-traded fund dropped 20.5%. Looks like 2022 will be “THE” year for biotech sector. In a recent note from Piper Sandler analyst Christopher Raymond and his colleagues, Raymond said that he recommended “selective buying” of biopharma stocks. On his list of top picks for the year are AbbVie (NYSEABBV), Horizon Therapeutics NASDAQ:HZNPNASDAQHZNP)(NYSE:BHVNNYSEBHVN, and Jazz Pharmaceuticals (NASDAQ:JAZZNASDAQ), among others.
A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSEBHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine.
